A Phase I Trial of Volasertib Plus Romidepsin in Patients With Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma

Trial Profile

A Phase I Trial of Volasertib Plus Romidepsin in Patients With Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Romidepsin (Primary) ; Volasertib (Primary)
  • Indications T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Nov 2016 Planned End Date changed from 1 Dec 2021 to 2 Nov 2016.
    • 29 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 2 Nov 2016.
    • 29 Nov 2016 Planned initiation date changed from 1 Dec 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top